TRAW · Categories · Form 4

TRAW - SEC Form 4 insider transactions

Traws Pharma Inc. (TRAW) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for TRAW

• 63d
  SEC Form 4 filed by Parker Charles Nolan

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Traws Pharma Inc.

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Traws Pharma Inc.

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Traws Pharma Inc.

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Director Cautreels Werner

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Traws Pharma Inc.

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Traws Pharma Inc.

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Traws Pharma Inc.

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Director Stover Jack E

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 92d
  SEC Form 4 filed by Director Shoemaker Mary Teresa

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Director Leaman John Harold was granted 4,058 shares (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Director Clarke Trafford was granted 6,157 shares (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Director Cautreels Werner was granted 4,874 shares, increasing direct ownership by 5% to 109,222 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Director Shoemaker Mary Teresa was granted 6,157 shares, increasing direct ownership by 4,561% to 6,292 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Director Stover Jack E was granted 6,157 shares, increasing direct ownership by 76,962% to 6,165 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Chief Executive Officer Dukes Iain D. was granted 36,943 shares, increasing direct ownership by 28% to 171,130 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Chief Science Officer Virology Pauza Charles David was granted 18,471 shares, increasing direct ownership by 19% to 115,971 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Chief Medical Officer Redfield Robert was granted 16,419 shares, increasing direct ownership by 17% to 113,919 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 176d
  Chief Operating Officer Savchuk Nikolay was granted 16,419 shares, increasing direct ownership by 12% to 150,606 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 197d
  SEC Form 4 filed by Director Leaman John Harold

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Chief Operating Officer Savchuk Nikolay

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Chief Medical Officer Redfield Robert

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Chief Science Officer Virology Pauza Charles David

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Chief Executive Officer Dukes Iain D.

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Director Cautreels Werner

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Director Stover Jack E

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Director Clarke Trafford

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 238d
  SEC Form 4 filed by Director Shoemaker Mary Teresa

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 239d
  SEC Form 4 filed by Director Leaman John Harold

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 352d
  SEC Form 4 filed by Director Clarke Trafford

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 352d
  SEC Form 4 filed by Director Stover Jack E

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 352d
  SEC Form 4 filed by Director Shoemaker Mary Teresa

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 352d
  SEC Form 4 filed by Director Cautreels Werner

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 428d
  Large owner Tpav, Llc disposed of 605,531 shares, closing all direct ownership in the company (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 476d
  Chief Executive Officer Cautreels Werner exercised 96,348 shares at a strike of $0.01, increasing direct ownership by 1,204% to 104,348 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 485d
  SEC Form 4 filed by Chief Financial Officer Guerin Mark Patrick

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 499d
  SEC Form 4 filed by Large owner Orbimed Advisors Llc

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 499d
  SEC Form 4 filed by Chief Executive Officer Cautreels Werner

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 499d
  SEC Form 4 filed by Large owner Tpav, Llc

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 499d
  SEC Form 4 filed by Chief Operating Officer Savchuk Nikolay

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 631d
  SEC Form 4 filed by Director Greenwood Luba

  4 - Traws Pharma, Inc. (0001130598) (Issuer)
• 672d
  Amendment: Executive Chairman Dukes Iain D. was granted 67,500 shares, increasing direct ownership by 101% to 134,187 units (SEC Form 4)

  4/A - Traws Pharma, Inc. (0001130598) (Issuer)
• 672d
  Amendment: Chief Operating Officer Savchuk Nikolay was granted 67,500 shares, increasing direct ownership by 101% to 134,187 units (SEC Form 4)

  4/A - Traws Pharma, Inc. (0001130598) (Issuer)
• 720d
  CFO Guerin Mark Patrick converted options into 5,500 shares and covered exercise/tax liability with 2,221 shares, increasing direct ownership by 9% to 39,255 units (SEC Form 4)

  4 - Traws Pharma, Inc. (0001130598) (Issuer)

Other TRAW categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends